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Background
Treatment of early and multiple cutaneous unresectable
recurrences is a major therapeutic problem with around
80% of patients relapsing within 5 years [1]. For lesions
refractory to elective treatments, electrochemotherapy
(ECT) involving electroporation combined with antineo-
plastic drug treatment appears to be a new potential
option [2]. This study was undertaken to analyze the
short- and long-term responses of lesions treated with
ECT with intravenous injection of bleomycin in mela-
noma patients with in-transit disease or distant cuta-
neous metastases.
Materials and methods
Between January 2007 and September 2012, 60 patients
with relapsed and refractory cutaneous melanoma metas-
tases or in-transit disease underwent 100 courses of ECT
with intravenous injection of bleomycin. Response to
treatment was evaluated three months after ECT. A long-
lasting response was defined as no cutaneous or in-transit
relapse after a minimum of six months.
Results
Three months after ECT, a complete response was
observed in 29 patients (48.4%), a partial response in
23 patients (38.3%) and no change or progressive disease
in 8 patients (13.3%). The objective response rate of all
treated lesions was 86.6%. Thirteen patients (44.8% of
complete responders) experienced a long-lasting response
to ECT and were disease-free after a mean duration of fol-
low-up of 27.5 months.
Conclusions
The favorable outcome obtained in the present study
demonstrates that ECT is a reliable, and effective proce-
dure that provides long-term benefit in terms of curative
and palliative treatment for unresectable cutaneous
lesions without adversely impacting the quality of life of
patients [3-7].
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